Bristol-Myers beats Wall St estimates, helped by Cancer drug Opdivo

NEW YORK (Reuters) - Bristol-Myers Squibb Co on Thursday posted better-than-expected first-quarter earnings, helped by growth from cancer drugs Opdivo and Yervoy and blood thinner Eliquis.